MENU
TIL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

TIL stock forecast, quote, news & analysis

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for TIL with price predictions
Nov 11, 2026

Momentum Indicator for TIL turns negative, indicating new downward trend

TIL saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 84 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 46 cases where TIL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

TIL moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for TIL entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TIL's RSI Oscillator exited the oversold zone, 31 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for TIL just turned positive on October 28, 2026. Looking at past instances where TIL's MACD turned positive, the stock continued to rise in 40 of 46 cases over the following month. The odds of a continued upward trend are 87%.

Following a +6.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where TIL advanced for three days, in 191 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

TIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.431) is normal, around the industry mean (3.498). P/E Ratio (-1.552) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. TIL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -14%. PEPG experienced the highest price growth at 115%, while KPTI experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company engaged in the reinsurance business

Industry Biotechnology

Industry
Precious Metals
Address
3963 Maple Avenue
Phone
+1 972 499-3350
Employees
17
Web
https://www.instilbio.com
Momentum Indicator for TIL turns negative, indicating new downward trend